The initial impact of a national BNT162b2 mRNA COVID-19 vaccine rollout
<h3>Objective</h3><p dir="ltr">This study examined the initial impact of a national BNT162b2 vaccine rollout on SARS-CoV-2 infections in Qatar.</p><h3>Methods</h3><p dir="ltr">All individuals who had completed ≥14 days of follow-up by 16...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , , , , |
| منشور في: |
2021
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513553621319680 |
|---|---|
| author | Ahmed Zaqout (9538566) |
| author2 | Joanne Daghfal (9538551) Israa Alaqad (20414108) Saleh A.N. Hussein (20414111) Abdullah Aldushain (20414114) Muna A. Almaslamani (9538548) Mohammed Abukhattab (9538614) Ali S. Omrani (9590116) |
| author2_role | author author author author author author author |
| author_facet | Ahmed Zaqout (9538566) Joanne Daghfal (9538551) Israa Alaqad (20414108) Saleh A.N. Hussein (20414111) Abdullah Aldushain (20414114) Muna A. Almaslamani (9538548) Mohammed Abukhattab (9538614) Ali S. Omrani (9590116) |
| author_role | author |
| dc.creator.none.fl_str_mv | Ahmed Zaqout (9538566) Joanne Daghfal (9538551) Israa Alaqad (20414108) Saleh A.N. Hussein (20414111) Abdullah Aldushain (20414114) Muna A. Almaslamani (9538548) Mohammed Abukhattab (9538614) Ali S. Omrani (9590116) |
| dc.date.none.fl_str_mv | 2021-07-01T00:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1016/j.ijid.2021.05.021 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/The_initial_impact_of_a_national_BNT162b2_mRNA_COVID-19_vaccine_rollout/28006094 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Health sciences Epidemiology Public health COVID-19 SARS-CoV-2 Coronavirus Vaccine BNT162b2 mRNA Qatar |
| dc.title.none.fl_str_mv | The initial impact of a national BNT162b2 mRNA COVID-19 vaccine rollout |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <h3>Objective</h3><p dir="ltr">This study examined the initial impact of a national BNT162b2 vaccine rollout on SARS-CoV-2 infections in Qatar.</p><h3>Methods</h3><p dir="ltr">All individuals who had completed ≥14 days of follow-up by 16 March 2021 after receiving the BNT162b2 vaccine were included. This study calculated incidence rates (IR) and their 95% confidence intervals (CI) during days 1–7, 8–14, 15–21, 22–28, and >28 days post-vaccination. Poisson regression was used to calculate incidence rate ratios (IRR) relative to the first 7-day post-vaccination period.</p><h3>Results</h3><p dir="ltr">A total of 199,219 individuals with 6,521,124 person-days of follow-up were included. SARS-CoV-2 infection was confirmed in 1877 (0.9%), of which 489 (26.1%) were asymptomatic and 123 (6.6%) required oxygen support. The median time from first vaccination to SARS-CoV-2 confirmation was 11.9 days (IQR 7.7–18.2). Compared with the first 7-day post-vaccination period, SARS-CoV-2 infections were lower by 65.8–84.7% during 15–21, 22–28, and >28 days (P < 0.001 for each). For severe COVID-19, the incidence rates were 75.7–93.3% lower during the corresponding time periods (P < 0.001 for each).</p><h3>Conclusion</h3><p dir="ltr">The results were consistent with an early protective effect of BNT162b2 vaccine against all degrees of SARS-CoV-2 severity.</p><h2>Other Information</h2><p dir="ltr">Published in: International Journal of Infectious Diseases<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.ijid.2021.05.021" target="_blank">https://dx.doi.org/10.1016/j.ijid.2021.05.021</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_564d0eea1ce488c79d5912cc9b9aaae6 |
| identifier_str_mv | 10.1016/j.ijid.2021.05.021 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/28006094 |
| publishDate | 2021 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | The initial impact of a national BNT162b2 mRNA COVID-19 vaccine rolloutAhmed Zaqout (9538566)Joanne Daghfal (9538551)Israa Alaqad (20414108)Saleh A.N. Hussein (20414111)Abdullah Aldushain (20414114)Muna A. Almaslamani (9538548)Mohammed Abukhattab (9538614)Ali S. Omrani (9590116)Health sciencesEpidemiologyPublic healthCOVID-19SARS-CoV-2CoronavirusVaccineBNT162b2mRNAQatar<h3>Objective</h3><p dir="ltr">This study examined the initial impact of a national BNT162b2 vaccine rollout on SARS-CoV-2 infections in Qatar.</p><h3>Methods</h3><p dir="ltr">All individuals who had completed ≥14 days of follow-up by 16 March 2021 after receiving the BNT162b2 vaccine were included. This study calculated incidence rates (IR) and their 95% confidence intervals (CI) during days 1–7, 8–14, 15–21, 22–28, and >28 days post-vaccination. Poisson regression was used to calculate incidence rate ratios (IRR) relative to the first 7-day post-vaccination period.</p><h3>Results</h3><p dir="ltr">A total of 199,219 individuals with 6,521,124 person-days of follow-up were included. SARS-CoV-2 infection was confirmed in 1877 (0.9%), of which 489 (26.1%) were asymptomatic and 123 (6.6%) required oxygen support. The median time from first vaccination to SARS-CoV-2 confirmation was 11.9 days (IQR 7.7–18.2). Compared with the first 7-day post-vaccination period, SARS-CoV-2 infections were lower by 65.8–84.7% during 15–21, 22–28, and >28 days (P < 0.001 for each). For severe COVID-19, the incidence rates were 75.7–93.3% lower during the corresponding time periods (P < 0.001 for each).</p><h3>Conclusion</h3><p dir="ltr">The results were consistent with an early protective effect of BNT162b2 vaccine against all degrees of SARS-CoV-2 severity.</p><h2>Other Information</h2><p dir="ltr">Published in: International Journal of Infectious Diseases<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.ijid.2021.05.021" target="_blank">https://dx.doi.org/10.1016/j.ijid.2021.05.021</a></p>2021-07-01T00:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1016/j.ijid.2021.05.021https://figshare.com/articles/journal_contribution/The_initial_impact_of_a_national_BNT162b2_mRNA_COVID-19_vaccine_rollout/28006094CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/280060942021-07-01T00:00:00Z |
| spellingShingle | The initial impact of a national BNT162b2 mRNA COVID-19 vaccine rollout Ahmed Zaqout (9538566) Health sciences Epidemiology Public health COVID-19 SARS-CoV-2 Coronavirus Vaccine BNT162b2 mRNA Qatar |
| status_str | publishedVersion |
| title | The initial impact of a national BNT162b2 mRNA COVID-19 vaccine rollout |
| title_full | The initial impact of a national BNT162b2 mRNA COVID-19 vaccine rollout |
| title_fullStr | The initial impact of a national BNT162b2 mRNA COVID-19 vaccine rollout |
| title_full_unstemmed | The initial impact of a national BNT162b2 mRNA COVID-19 vaccine rollout |
| title_short | The initial impact of a national BNT162b2 mRNA COVID-19 vaccine rollout |
| title_sort | The initial impact of a national BNT162b2 mRNA COVID-19 vaccine rollout |
| topic | Health sciences Epidemiology Public health COVID-19 SARS-CoV-2 Coronavirus Vaccine BNT162b2 mRNA Qatar |